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ABSTRACT 
Objectives: Lewy body dementia (LBD) is the second most prevalent neurodegenerative 
dementia, and it causes more morbidity and mortality than Alzheimer's disease. Several genetic 
associations of LBD have been reported, and their functional implications remain uncertain. 
Hence, we aimed to do a systematic review of all gene expression studies that investigated 
people with LBD for improving our understanding of LBD molecular pathology and for 
facilitating discovery of novel biomarkers and therapeutic targets for LBD. 
Methods: We systematically reviewed five online databases (PROSPERO protocol: 
CRD42017080647) and assessed the functional implications of all reported differentially 
expressed genes (DEG) using Ingenuity Pathway Analyses.  
Results: We screened 3,809 articles and identified 31 eligible studies. 1,242 statistically 
significant (p<0.05) DEGs including 70 microRNAs have been reported in people with LBD. 
Expression levels of alternatively spliced transcripts of SNCA, SNCB, PRKN, APP, RELA, and 
ATXN2 significantly differ in LBD. Several mitochondrial genes and genes involved in 
ubiquitin proteasome system and autophagy lysosomal pathway were significantly 
downregulated in LBD. Evidence supporting chronic neuroinflammation in LBD was 
inconsistent. Our functional analyses highlighted the importance of RNA-mediated gene 
silencing, neuregulin signalling, and neurotrophic factors in the molecular pathology of LBD. 
Conclusions: α-synuclein aggregation, mitochondrial dysfunction, defects in molecular 
networks clearing misfolded proteins, and RNA-mediated gene silencing contribute to 
neurodegeneration in LBD. Larger longitudinal transcriptomic studies investigating biological 
fluids of people living with LBD are needed for molecular subtyping and staging of LBD. 
Diagnostic biomarker potential and therapeutic promise of identified DEGs warrant further 
research.  
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Summations: 
1. 1,242 differentially expressed genes including 70 microRNAs have been reported in people 
with LBD.  
2. Several mitochondrial genes and genes involved in ubiquitin proteasome system and 
autophagy lysosomal pathway were significantly downregulated in people with LBD.  
3. Our functional analyses highlighted the importance of RNA-mediated gene silencing, 
neuregulin signalling, and neurotrophic factors in LBD molecular pathology. 
 
Considerations: 
1. This systematic review has excluded studies that were not published in English. It did not 
include studies that investigated animal models or cell lines. 
2. All included studies were small cross-sectional studies, and there was substantial 
heterogeneity among the included studies.  
3. Majority of the included studies have employed relative quantification methods, so it was 
not possible to do combined analyses using their findings.  
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Introduction 
Lewy Body Dementia (LBD) includes of two overlapping clinical syndromes, 
Dementia with Lewy Bodies (DLB) and Parkinson’s Disease Dementia (PDD) (1). DLB is the 
second most common neurodegenerative dementia, and its incidence rate has been estimated 
as 112 per 100,000 for those over 65 (2,3).  LBD leads to increased mortality (4), earlier nursing 
home admissions, more frequent falls, worse quality-of-life, higher costs (5) and more 
caregivers’ burden than Alzheimer’s disease (AD). DLB is underdiagnosed in many clinical 
settings, and nearly 50% of  people with DLB reportedly remain misdiagnosed in the UK (6). 
Missing the diagnosis of LBD and treating associated neuropsychiatric symptoms with 
antipsychotic medications risk life threatening adverse effects such as neuroleptic malignant 
syndrome in people with LBD. Currently, we do not have a reliable biological fluid based 
diagnostic biomarker or a disease modifying drug for LBD. Improving our knowledge of 
molecular mechanisms underlying neurodegeneration in LBD is essential for discovering 
reliable diagnostic biomarkers and novel therapeutic targets for LBD (3,7). 
Although the onset of most LBD appear sporadic, several studies have reported familial 
aggregation of LBD and its core clinical features (8,9). The heritability of DLB has been 
estimated as 59.9%, and the genetic risk factors for DLB are likely to be independent from 
known risk variants of AD and Parkinson’s disease (PD) (10). Two genome wide association 
studies (GWAS) (11,12) and a genome wide analysis of copy number variants (13) have 
investigated the genetic associations of DLB. There has not been any specific GWAS 
investigating people with PDD. Genetic associations between LBD and the variants in APOE, 
GBA, SNCA and MAPT have been replicated by two or more studies. Other reported genetic 
associations of LBD that need further replication include the variants in ADGRG7, BCHE-K, 
BCL7C, CHRFAM7A, CNTN1, GABRB3, LAPTM4B, mtDNA, MSR1, NME1, NME2, NOS2A, 
PDZD2, PSEN1, SCARB2, SPAG9, TFG, TREM2, UCHL1, and ZFPM1. 
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Genetic association studies cannot clarify the functional implications of the identified 
genetic associations. Gene expression studies investigating Ribonucleic acid (RNA) levels (14) 
are necessary for quantifying transcriptional changes and for understanding the effects of gene 
expression regulation and alternative splicing. Unlike genetic associations, gene expression 
changes are dynamic and tissue specific. As gene expression differs with disease progression, 
gene expression studies help staging diseases and identifying RNA-based therapeutic targets 
(15). Gene expression studies in people with LBD have highlighted the importance of 
alternative splicing of α-synuclein in the molecular pathogenesis of LBD. Increased expression 
of α-synuclein-112, and decreased expression of α-synuclein-126 in the post-mortem frontal 
cortices of people with LBD have been reported (16). Gene expression profiling of post-
mortem LBD brains and biological fluids of people living with LBD can advance our molecular 
level mechanistic understanding of neurodegeneration in LBD. This will facilitate identifying 
reliable diagnostic biomarkers and novel therapeutic targets for LBD. Considering the need for 
a comprehensive summary of all available evidence from the gene expression studies in people 
with LBD, we aimed to conduct the first systematic review on this topic. 
 
Materials and Methods  
Study design: The protocol for this systematic review has been registered in the international 
prospective register of systematic reviews (PROSPERO protocol CRD42017080647; available 
at http://www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD42017080647).  
Search strategy: We systematically searched the following five online databases: 
MEDLINE/PubMed (since 1946), EMBASE (since 1974), PsycINFO (since 1806), Web of 
Science (since 1900), and OpenGrey (since 2004). The search strategy included combinations 
of population search terms and exposure search terms. The population search terms were 
(‘Lewy’ OR ‘Parkinson*’) AND ‘Dementia’. The exposure search terms included (Gene* 
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AND express*) OR (RNA) OR (qPCR) OR (RNA AND Seq*). Reference lists of the studies 
included in the review were explored for identifying other potentially eligible studies. All 
studies that were published on or before 1st January 2018 were considered. Studies that were 
not published in English were not included.  
Eligibility criteria: We included all gene expression studies that satisfied the following 
eligibility criteria, i) They were human studies. Studies on animal models and  in vitro studies 
investigating human tissue derived cell lines were excluded, ii) They presented original 
research data, iii) Participants in at least one study group were clinically diagnosed to have 
DLB or PDD or LBD. Studies that solely included people with other types of dementia or PD 
without dementia were excluded, iv) There was a control group in which LBD was clinically 
ruled out, v) They investigated expression levels of at least one gene.  
Study selection: We merged our search results across the databases and removed duplicates 
using the RefWorks software (ProQuest LLC, USA). We excluded the abstracts that did not 
mention investigating gene expression changes in people with LBD. We attempted retrieving 
full texts of all potentially eligible abstracts and assessed the eligibility of the full-text papers. 
The studies that failed to meet one or more of the eligibility criteria were excluded. When a 
conference abstract was not accompanied by its full text, we requested further details from the 
corresponding author, if the contact information was provided. If the corresponding author did 
not respond to our request within 14 days, we excluded that abstract.   
Quality assessment: We assessed the quality of eligible studies using a tool (Supplementary 
information table-1), adapted from the Quality of genetic association studies tool (Q-Genie) 
(17,18). The tool assessed the following 11 dimensions, (i) the rationale for study, (ii) selection 
and definition of people with LBD, (iii) selection and comparability of comparison groups, (iv) 
technical assessment of gene expression, (v) non-technical aspects of assessment of gene 
expression, (vi) other sources of bias, (vii) sample size and power, (viii) a priori planning of 
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statistical analyses, (ix) statistical methods and control for confounding, (x) testing of 
assumptions and inferences for gene expression analyses, and (xi) appropriate interpretation of 
the study results.  Each dimension was scored on a scale from one (poor) to seven (excellent), 
so the total scores could range from 11 to 77. 
Data extraction: We extracted the following data, i) population characteristics including their 
mean age, ethnicity, and severity of illness (ii) sample size in each study group, iii) case 
definition, iv) investigated genes and their transcripts, v) investigated tissue, vi) methods for 
analysing gene expression changes, vii) differential fold changes between the study groups 
with their p-values, viii) statistical correction for multiple testing, ix) statistical analyses 
addressing the effects of potential confounders.  
Data synthesis: A descriptive synthesis was carried out using the extracted data and major 
findings of each included study. We have synthesized the data by listing the reported gene 
expression changes in post-mortem brain tissue and in biological fluids of people with DLB or 
PDD. We have summarised the reported findings on alternative splicing and on differentially 
expressed microRNA (miRNA) in people with DLB or PDD separately. 
Data analyses: Functional implications of identified differentially expressed genes (DEGs) 
(p<0.05) were analysed by the ingenuity pathway analyses (IPA) using the Ingenuity 
knowledge base (Ingenuity, Redwood City, USA). IPA is a powerful functional analysis tool 
that helps identifying potential biomarkers within the context of biological systems. Our IPA 
analysis settings included stringent filters with only experimentally observed relationships, and 
we identified disrupted functional pathways and dysfunctional molecular networks after 
Benjamani-Hochberg false discovery rate (FDR) at 5% correction in people with LBD.  
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Results  
Included studies:  Figure-1 presents the Preferred Reporting Items for Systematic Review and 
Meta-Analyses (PRISMA) (19) flow chart describing the process of identifying all eligible 
studies.  We identified and screened 2,379 papers after removing the duplicates and found 31 
papers eligible to be included in this systematic review. Among the 31 included studies, 23 
measured gene expression changes using quantitative polymerase chain reactions (qPCR). 
There were three studies using gene expression microarrays (20-22) and three studies using 
next-generation RNA sequencing (RNA-Seq) (23-25). One study employed northern blotting 
(26), and another used RNAse protection assay (27). Supplementary information table-2 
presents the quality assessment scores of all included studies. Their quality assessment total 
scores ranged from 40 to 56 (median=49), and there were 23 studies with quality assessment 
total scores above 45.  
Overall, 369 individual people with LBD and 368 controls were included in these 31 
studies. Among them, there were 294 people with DLB and 75 people with PDD. Most of the 
studies have investigated post-mortem brain tissue, obtained from various brain banks. 
Investigated regions of brain tissue include frontal cortex, temporal cortex, motor cortex, 
medial temporal gyrus, superior parietal gyrus, superior frontal gyrus, substantia nigra, 
hippocampus, anterior cingulate cortex, locus coeruleus, caudate nucleus and pons. All but one 
study have reported the details of brain bank, and the investigated region of brain tissue. There 
were only three studies (26,28,29) that have investigated peripheral blood samples, and there 
was only one study (30) that has investigated cerebrospinal fluid (CSF). Supplementary 
information table-3 presents the list of all 1,242 reported DEGs in people with DLB. There 
were 1,236 reported DEGs in post-mortem brain tissue, and six DEGs in biological fluids have 
been reported so far. 
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DEGs in post-mortem DLB brains: Table-1 presents a summary of studies that have 
investigated gene expression changes in post-mortem DLB brains. α-synuclein encoding SNCA 
total gene expression levels did not differ significantly in people with DLB, but its shorter 
isoforms have been found to be significantly upregulated. Reported DEGs in post-mortem DLB 
brains included genes involved in protein signalling, folding and degradation. UCHL-1 
encoding ubiquitin C-terminal hydrolase L1, SNCAIP encoding synphilin-1, and PRKN 
encoding Parkin contribute to the ubiquitin proteasome system (UPS) that is essential for the 
regulation and removal of misfolded proteins. Statistically significant downregulation of 
UCHL-1 and PRKN and significant upregulation of SNCAIP have been reported in DLB brains 
(31-33). The autophagy lysosomal pathway (ALP) is crucial for protein degradation (34). GBA 
gene encoding lysosomal enzyme beta-glucocerebrosidase was significantly downregulated in 
DLB brains (35). β-site amyloid precursor protein (APP) cleaving enzyme encoding BACE1 
was found to be significantly upregulated in DLB (36). Moreover, genes involved in synaptic 
regulation and neurotransmission such as TH, ADRA2C and ADRA1D were significantly 
differentially expressed in post-mortem DLB brains, but these findings have not been 
replicated so far (37). Furthermore, HSP70 and HSP27 were found to be upregulated up to 
three-fold in DLB brains (38,39). 
DEGs in post-mortem PDD brains: Six studies have investigated gene expression changes 
in post-mortem PDD brains (21,24,25,27,40,41) (Table-2). A RNA-Seq study that investigated 
the posterior cingulate cortical transcriptomics of people with PDD has reported statistically 
significant upregulation of genes associated with protein folding pathways such as HSP40 and 
DNAJB1, and downregulation of genes associated with hormonal activity, ion transport, nerve 
growth and cytoskeleton structure (24). Inflammation associated CSF3 and SELE were 
significantly upregulated, and PENK, CRH, and SST were significantly downregulated in 
people with PDD (24). Another study that investigated the gene expression changes in posterior 
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cingulate cortices of people with PDD using gene expression microarrays identified 556 DEGs 
(p<0.01) in PDD. There was downregulation of genes involved in neurite growth and cell 
adhesion such as KIF21A, DYNC2LI1 and TBCA (21). Another study that employed RNAse 
protection assay has reported significant upregulation of G protein-coupled receptor (GPCR) 
pathways related ARRB2 (p<0.001), ARR3 (p<0.001), GRK3 (p<0.01) and GRK5 (p<0.05) in 
post-mortem PDD brains (27). 
DEGs in biological fluids of people with LBD: There were only three studies which have 
investigated gene expression changes in biological fluids of people with DLB. Two of them 
have investigated peripheral leukocytes (28,29), and the third has investigated CSF (30). There 
was only one study that specifically investigated gene expression changes in biological fluids 
of people with PDD (26). SNCA total gene expression levels did not differ significantly, but its 
isoform SNCA-126 level was significantly upregulated in peripheral leukocytes of people with 
DLB (29). Another study has assessed expression levels of 11 mitochondrial genes in 
peripheral leukocytes, and found significant (p<0.05) downregulation of MT-ATP8, MT-CO2, 
MT-CO3 and MT-ND2 in people with DLB (28). Only MIR-125B was significantly 
downregulated in CSF of people with DLB (p=0.03) (30). Moreover, expression levels of 
HSP70 did not differ significantly in peripheral mononuclear blood cells of people with PDD 
(26).  
Potential miRNA biomarkers for LBD: Four studies have reported differential expression of 
miRNAs in people with DLB (22,23,30,42), and two more have investigated differentially 
expressed miRNAs in people with PDD (24,25). 70 differentially expressed miRNA in people 
with LBD have been identified so far (Table-3) (Supplementary information table-3). MIR-
125B was significantly differentially expressed in both post-mortem DLB temporal cortices 
and CSF of people living with DLB (30,42). Differential expression levels of 36 miRNAs in 
prefrontal cortices could distinguish PDD from PD with 81.2% sensitivity and 88.9% 
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specificity (25). Moreover, a study that investigated anterior cingulate cortices of people with 
DLB using RNA-Seq has identified 14 potential upstream regulatory miRNAs after appropriate 
multiple testing correction (23) (Table-3). 
Importance of alternative splicing in LBD: Expression levels of multiple isoforms of SNCA, 
SNCB, PRKN, and APP have been evaluated in people with DLB. Four alternatively spliced 
transcripts of SNCA, SNCA-98, SNCA-112, SNCA-126, and SNCA-140, have been studied. 
SNCA-98 was expressed 2.7 times more in frontal cortices of people with DLB (p<0.05) (43). 
Similarly, SNCA-112 expression levels were upregulated in people with DLB by twofold, when 
compared with controls without cognitive impairment (p=0.002), and by threefold, when 
compared with people with AD (p<0.001). Four-fold downregulation (p<0.001) in frontal 
cortices, and two-fold upregulation in peripheral leukocytes of SNCA-126 in people with DLB 
have been reported (16,29). Significant (p=0.008) downregulation of SNCA-140 in DLB brains 
(44) has been reported, but another study has failed to replicate this finding in frontal cortices 
and caudate nuclei of people with DLB (41). Upregulation of SNCA-140 levels in temporal 
cortices, and its downregulation in caudate nuclei of people with PDD has been reported (40). 
Two transcript variants (TV) of SNCB have been investigated in people with LBD (41,45). 
Expression levels the alternatively spliced isoforms, SNCB-TV1 and TV2, varied across 
different brain regions. SNCB-TV1 and TV2 were significantly downregulated in temporal and 
frontal cortices, and SNCB-TV1 was significantly upregulated in caudate nuclei of people with 
DLB. SNCB-TV1 and TV2 were significantly upregulated in temporal cortices and caudate 
nuclei of people with PDD (40,41). Levels of both SNCB transcripts were significantly reduced 
in pons of people with PDD (40).  
Three major isoforms of APP, APP-695, APP-751, and APP-770  have been 
investigated in people with DLB. People with DLB had significantly higher levels of APP-770 
(p<0.05) and significantly lower levels of APP-695. Results on APP-751 expression levels 
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were inconsistent (46,47). Moreover, significantly (p=0.02) lower levels of PRKN-TV7 has 
been reported in people with DLB (48). Furthermore, another study has investigated the 
importance of alternative splicing in posterior cingulate cortices of people with PDD using  
RNA-Seq and  SpliceSeq (49) software (24). There was 2.6 fold overexpression of alternatively 
spliced isoforms of RELA, compared to its main transcript, in people with PDD. More than 
threefold downregulation of alternatively spliced isoforms of ATXN2 in PDD was found (24). 
Functional analyses of reported DEGs in LBD: We investigated the functional implications 
of the 1,242 reported DEGs (p<0.05) using IPA. Movement disorders (p=2.42X10-9), disorders 
of basal ganglia (p=2.71X10-9), schizophrenia (p=3.29X10-8), immune response of brain 
(p=3.48X10-7), neuronal death and survival (p=7.34X10-6), tauopathy of hippocampus 
(p=2.96X10-5), neuronal morphology (p=4.28X10-5), synaptic transmission (p=3.93X10-4), and 
tauopathy of amygdala (p=4.02X10-4) associated genes were significantly enriched among the 
reported DEGs in people with LBD. Figure-2A presents the molecular pathways that were 
significantly enriched among the LBD DEGs after Benjamini-Hochberg false discovery rate 
(FDR) correction at 5%. Initiation of protein translation related EIF2 signalling, neuronal 
maintenance related neuregulin signalling, oxidative damage, apoptosis, and neuronal survival 
related PEDF signalling, signal transduction via phosphorylation and cell survival related 
mTOR signalling, and gene transcription regulating HMGB1 signalling pathways associated 
genes were significantly enriched among the LBD DEGs after FDR correction (Supplementary 
information table-4). The genes, associated with neuroinflammation signalling pathway, were 
significantly enriched among LBD DEGs after FDR correction, and they included 21 
upregulated and 14 downregulated DEGs. Moreover, movement of myeloid cells related genes 
were significantly enriched among the downregulated LBD DEGs (z=-2.24; p=3.23X10-4).  
 Our IPA upstream analyses and causal network analyses revealed that inhibition of 
TCF7L2 encoding a transcription factor (p=4.44X10-21) and of neurotrophic BDNF 
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(p=7.39X10-6) were likely upstream biological causes leading to the reported gene expression 
changes in people with LBD (50). Furthermore, they highlighted the importance of RNA-
mediated gene silencing in the molecular pathology of LBD. AGO2 (p=2.22X10-8) encoding 
protein argonaute-2 that is essential for the formation RNA-induced silencing complex (RISC), 
and DICER1 (p=7.57X10-6) encoding dicer that cleaves miRNA and small interfering RNA 
(siRNA) and activates RISC were identified as potential upstream biological causes for the 
reported gene expression changes in LBD. Our IPA network analyses (Supplementary 
information table-5) showed that several reported DEGs in LBD including APBA2, HTRA2, 
ENO2, and MIR17 directly or indirectly interact with APP and Tau encoding APP and MAPT 
(Figure-2B). This dysfunctional molecular network can explain neurodegeneration in LBD and 
varying degrees of comorbid AD pathology, reported in many post-mortem LBD brains 
(Figure-2B).  PD and DLB associated genes, GBA, PRKN, and SCARB2, directly interact with 
SNCA that interacts with L-3,4-dihydroxyphenylalanine (L-DOPA) synthesising Tyrosine 
Hydroxylase gene (TH) and with PSEN1 encoding an essential protein for γ-secretase complex 
that cleaves β-amyloid from APP. Reported downregulation of PSEN1 can increase α-
synuclein aggregation independent of its γ-secretase activity, and associated downregulation 
of SNCB further increases α-synuclein aggregation that leads to formation of Lewy bodies (51). 
Figure-2C presents a dysfunctional molecular network including differential expression of 
these genes and their interactions. Figure-2D presents the complex interactions between 
neurotrophic BDNF and RNA-mediated gene silencing, regulated by DICER1, AGO2, and 
associated miRNAs. This dysfunctional molecular network can influence gene expression of 
many downstream genes and can impact neuronal survival and maintenance in people with 
LBD. 
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Discussion 
This is the first systematic review of all gene expression studies that have investigated 
people with LBD. We have listed all reported DEGs in people with LBD and have investigated 
their functional implications. Our functional analyses advance our understanding of molecular 
mechanisms underlying neurodegeneration in LBD. The strengths of this systematic review 
include its broad eligibility criteria, following PRISMA guidelines, and searching multiple 
databases including grey literature. Its limitations are excluding studies that were not published 
in English, not including studies that investigated animal models or cell lines, and substantial 
heterogeneity among the included studies. All included studies were small, and the smallest 
study has included only four people with LBD (42). The studies have not reported sample size 
estimation or power analysis, so type-II error is likely. They differed widely on their population 
characteristics, case definitions, selection of controls, methods for measuring gene expression 
changes, and statistical analyses. Many studies did not employ statistical corrections for 
multiple testing. Majority of the studies have employed relative quantification qPCR, so it was 
not possible to do combined analyses using their findings. Moreover, another RNA-Seq study 
that investigated anterior cingulate and dorsolateral prefrontal cortical transcriptomics of 
people with DLB and PDD was published after the completion of this systematic review in 
June 2019 (52). It identified 12 genome-wide significant DEGs (MPO, SELE, CTSG, ALPI, 
ABCA13, GALNT6, SST, RBM3, CSF3, SLC4A1, OXTR, and RAB44) in people with LBD. 
Although α-synuclein aggregation is the key initial step in the formation of Lewy bodies 
(53), α-synuclein encoding SNCA total gene expression levels often do not differ significantly 
in people with LBD. Two of its alternatively spliced shorter isoforms, SNCA-98 and SNCA-
112, have increased propensity for aggregation (16), and they were found to be significantly 
upregulated in DLB brains (43). This highlights the need for further in-depth investigation of 
RNA biology, alternative splicing, and expression levels of individual transcripts in people 
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with LBD and other α-synucleinopathies (54). Upregulation of SNCA-126 could be detected in 
peripheral leukocytes of people living with DLB (29), and diagnostic biomarker potential of 
peripheral levels of SNCA transcripts warrant further research. Moreover, alternative splicing 
of β-synuclein encoding SNCB also plays an important role in the pathology of α-
synucleinopathies (55). β-synuclein prevents α-synuclein inhibiting proteasomes, and it 
inhibits further α-synuclein aggregation (45). Expression levels of the two SNCB transcripts 
differ between DLB brains with and without co-existent AD pathology (41). SNCB-TV1 and 
TV2 were significantly downregulated in temporal cortices of people with DLB, and they were 
significantly upregulated in temporal cortices of people with PDD (40,41). Further 
investigation of expression levels of individual transcripts of SNCB may lead to molecular 
subtyping of LBD (41). 
Lewy bodies are complex structures, and they are made of more than 80 distinct 
proteins (56). Available gene expression findings in people with LBD highlight the defects in 
molecular networks clearing abnormal proteins than overexpression of a few pathogenic genes. 
Optimal functioning of ALP and UPS is essential for the degradation of misfolded proteins 
(57). Prior studies, which mainly focussed on expression levels of genes associated with AD 
or PD, have indicated dysfunctional ALP and UPS contributing to neurodegeneration in LBD. 
They have reported statistically significant downregulation of UCHL-1, PRKN, and GBA in 
people with LBD (31-33,35). Recent transcriptomic studies have advanced our understanding 
of dysfunctional molecular networks involving ALP and UPS in people with LBD (20-25,52). 
Decreased expression of GBA impairs lysosomal protein degradation and leads to α-synuclein 
aggregation and neurotoxicity in stem cell derived neurons (58). Aggregated α-synuclein can 
set off a vicious cycle by inhibiting neuronal lysosomal activity further (58). SCARB2 encodes 
a lysosomal membrane protein that transports GBA to lysosomes (59), and its downregulation 
may impair the ALP further in people with LBD. GBA, PRKN, and SCARB2 directly interact 
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with SNCA and they interact indirectly with TH, SNCB, and PSEN1. This dysfunctional 
network and the decreased expression of UCHL1 that is essential for the hydrolysis of 
misfolded proteins by neuronal UPS (60,61) exacerbate α-synuclein aggregation and 
cytoplasmic accumulation of other misfolded proteins. 
Significantly decreased expression levels of mitochondrial genes involved in energy 
metabolism have been reported in people with LBD. Significant downregulation of MT-ATP8, 
MT-CO2, MT-CO3 and MT-ND2 could be measured in peripheral leukocytes of people with 
DLB (28). Reduced levels of mitochondrial complex I activity and oxygen uptake in DLB 
brains have been reported (62,63). Moreover, prior genetic association studies have found 
significant associations of LBD with mtDNA haplogroup H (64) and TFAM encoding 
mitochondrial transcription factor A (65). A recent RNA-Seq study and subsequent analysis of 
metabolic reprogramming in LBD brains by genome scale metabolic modeling (66) have 
highlighted the importance of mitochondrial dysfunction in LBD pathology (52). 
Mitochondrial dysfunction may set off a vicious cycle by generating more reactive oxygen 
species, which can lead to more mitochondrial oxidative damage (67). Reactive oxygen species 
and consequent oxidative stress lead to α-synuclein aggregation that in turn impair more 
mitochondria (67). Further studies are warranted for investigating associated molecular 
mechanisms as well as the biomarker and therapeutic potential of mitochondrial transcripts in 
LBD. 
Our functional analyses of reported DEGs highlighted the importance of RNA-
mediated gene silencing, neuregulin signalling, downregulation of neurotrophic factors in the 
molecular pathology of LBD. Downstream regulatory effects of decreased expression of 
neurotrophic BDNF may explain many reported gene expression changes in people with LBD 
(50). BDNF interacts with AGO2 and DICER1, which were found to be upregulated in people 
with LBD. AGO2 is essential for the formation of RISC and DICER1 is important for the 
17 
 
activation of RISC. Consequent RNA-mediated gene silencing may lead to downregulation of 
several downstream genes, related to neuronal survival and maintenance in people with LBD.  
Moreover, several reported DEGs in LBD interact with APP and MAPT. BACE1 expression 
levels were significantly upregulated in people with DLB (36), and there is a two-way 
relationship between α-synuclein aggregation and β-amyloid secretion (68). These findings 
may explain varying degrees of co-existent amyloid and Tau pathology in people with LBD.  
Unlike AD (69), available gene expression studies have provided inconsistent evidence 
for the presence of chronic neuroinflammation in people with LBD. Inflammation associated 
genes were significantly upregulated in people with PDD (21). However, a gene expression 
microarray study and a RNA-Seq study have documented statistically significant 
downregulation of several inflammation associated genes including IL1B, IL2, IL6, CXCL2, 
CXCL3, CXCL8, CXCL10, and CXCL11 in post-mortem DLB brains (20,52). TNF was 
upregulated only in rapidly progressive DLB (70), and another study has found upregulation 
of IL6 in hippocampi of people with DLB (n=5) (71).  However, these findings have not been 
replicated. Moreover, a recent transcriptomic and proteomic study has reported lack of 
evidence for microglia mediated neuroinflammation in post-mortem pulvinar of people with 
DLB (72). Optimal microglial activation is essential for neuronal survival and synaptic 
plasticity (73). Decreased expression of inflammation associated genes leading to impaired 
neuronal survival rather than chronic neuroinflammation may explain neurodegeneration in 
DLB (52). The differential expression levels of inflammation associated genes may help 
distinguishing DLB from PDD and AD, and their diagnostic and prognostic biomarker 
potential warrant further research. 
Each neurodegenerative disorder is hypothesised to have its own unique peripheral 
miRNA signature (74). We have listed 70 miRNA that were found to be differentially 
expressed in people with LBD, and their biomarker and therapeutic potential need further 
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investigation. Identifying differentially expressed miRNA in post-mortem LBD brains 
advances our molecular level mechanistic understanding. However, discovery of clinically 
adoptable diagnostic biomarkers requires identifying differentially expressed miRNA in 
biological fluids of people living with LBD (30). Despite their vulnerability for degradation, 
RNA, especially miRNA, remain stable in biological fluids by being either bound to protein 
complexes or encapsulated within blood cells or extracellular vesicles (EV) (75). Only one 
study has evaluated miRNA expression changes in biological fluids of people with LBD (30), 
and there has not been any systematic research investigating the EV RNA expression levels in 
people with LBD. CSF small EVs can transmit α-synuclein aggregation in-vitro (76). Small 
EVs can cross blood brain barrier (77), and they transport RNA between brain and peripheral 
circulation. Diagnostic biomarker potential of small EV RNA, enriched for neuronal origin, is 
increasingly recognised (78,79), and the need for more studies investigating small EV RNA in 
people with LBD cannot be overemphasised.  
Notwithstanding the extent of research on gene expression changes in people with PD 
without dementia, there is a scarcity of studies investigating these changes in people with PDD. 
The nosological validity of DLB and the diagnostic boundaries between DLB and PDD 
continue to be debatable, because the clinical presentations of advanced stages of DLB and 
PDD are often identical (80). Prevailing sparse evidence that comes almost exclusively from 
post-mortem brain tissue of people with clinically advanced PDD have indicated limited 
overlap between DEGs in DLB and PDD. Transcriptomes of DLB and PDD may display more 
pronounced differences during earlier clinical stages. We suggest more transcriptomic studies 
investigating biological fluids of people living with DLB and PDD for advancing our 
understanding of molecular differences between these two clinically overlapping disorders. All 
studies, included in this systematic review, have expressed gene expression changes at only 
one point of time. Gene expression changes are dynamic, and they differ with disease 
19 
 
progression, so we suggest future gene expression studies investigating the longitudinal gene 
expression changes in biological fluids of people living with LBD.  
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Figure legends 
Figure-1: The Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISMA) flow chart. 
 
Figure-2: Functional analyses of reported differentially expressed genes (DEG) in people with 
Lewy Body Dementia (LBD) 
2.A. Canonical pathways that were enriched among the reported DEG in people with LBD. 
Green represents downregulated genes, and red represents upregulated genes. Yellow 
line presents the p-values after Benjamini-Hochberg false discovery rate (5%) 
correction. 
2.B. A dysfunctional network of reported DEG may lead to amyloidopathy and tauopathy 
in LBD. 
2.C. A dysfunctional molecular network involving α-synuclein, presenilin 1, and tyrosine 
hydroxylase may explain α-synuclein aggregation and neurodegeneration in LBD. 
2.D. A dysfunctional molecular network involving brain derived neurotrophic factor, dicer 
1, and argonaute highlights the importance of neurotropic factors and RNA silencing 
complexes in the pathophysiology of LBD. 
 2.(B-D). Green represents downregulated genes, and red represents upregulated genes. Solid 
lines represent direct interactions and dotted lines represent indirect interactions. 
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